PubMed Health⌕ Search

Biomedical subjects

Mary Reid

Publications and source records attributed to Mary Reid.

7 recordsLinked to original sources
PubMed2006

Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment.

BACKGROUND: This is a preliminary report of an ongoing prospective bimodality lung cancer surveillance trial for high-risk patients. Bimodality surveillance incorporates autofluorescence bronchoscopy (AFB) and spiral CT (SCT) scanning in high-risk patients as a primary lung cancer surveillance strategy, based entirely on risk factors. AFB was used for surveillance and findings were compared with conventional sputum cytology for the detection of malignancy and pre-malignant central airway lesions. METHODS: 402 patients registering at Roswell Park Cancer Institute were evaluated with spirometric testing, chest radiography, history and physical examination, of which 207 were deemed eligible for the study. For eligibility, patients were required to have at least two of the following risk factors: (1) > or =20 pack year history of tobacco use, (2) asbestos-related lung disease on the chest radiograph, (3) chronic obstructive pulmonary disease with a forced expiratory volume in 1 s (FEV(1)) <70% of predicted, and (4) prior aerodigestive cancer treated with curative intent, with no evidence of disease for >2 years. All eligible patients underwent AFB, a low-dose SCT scan of the chest without contrast, and a sputum sample was collected for cytological examination. Bronchoscopic biopsy findings were correlated with sputum cytology results, SCT-detected pulmonary nodules and surveillance-detected cancers. To date, 186 have been enrolled with 169 completing the surveillance procedures. RESULTS: Thirteen lung cancers (7%) were detected in the 169 subjects who have completed all three surveillance studies to date. Pre-malignant changes were common and 66% of patients had squamous metaplasia or worse. Conventional sputum cytology missed 100% of the dysplasias and 68% of the metaplasias detected by AFB, and failed to detect any cases of carcinoma or carcinoma-in-situ in this patient cohort. Sputum cytology exhibited 33% sensitivity and 64% specificity for the presence of metaplasia. Seven of 13 lung cancers (58%) were stage Ia or less, including three patients with squamous cell carcinoma. Patients with peripheral pulmonary nodules identified by SCT scanning of the chest were 3.16 times more likely to exhibit pre-malignant changes on AFB (p<0.001). CONCLUSION: Bimodality surveillance will detect central lung cancer and pre-malignancy in patients with multiple lung cancer risk factors, even when conventional sputum cytology is negative. AFB should be considered in high-risk patients, regardless of sputum cytology findings.

Adult↗
PubMed2004

Accuracy of self-reported smoking status among participants in a chemoprevention trial.

BACKGROUND: Exposure to tobacco products is readily assessed through self- or interview-administered questionnaires. Degree of misreporting among participants in chemoprevention trials is unknown. We assessed the level of discrepancy between self-reported smoking exposure and plasma cotinine among participants in a chemoprevention trial. METHODS: Analyses were conducted among 824 men and women who participated in a dietary trial of adenoma recurrence. Smoking exposure was ascertained through self-administered questionnaires at three time-points. Plasma cotinine was measured by gas chromatography among 283 never, 446 former and 95 current self-reported smokers. Sensitivity and specificity were assessed using various plasma cotinine cut-points. RESULTS: Degree of misclassification for self-reported current smokers was minor (0-3%), regardless of cotinine cut-point used. Using a cut-point of 20 ng/ml, which takes into account exposure to environmental tobacco smoke among nonsmokers, sensitivity and specificity were 98.9% and 80.2%, respectively. CONCLUSIONS: These data indicate that degree of misreport for current smokers is extremely low; however, approximately 20% of self-reported never smokers misreport their exposure, suggesting that validation of self-report is needed for these individuals.

Adenoma↗
PubMed2004

The characteristics and training of professionals in cancer prevention and control: a survey of theAmerican Society for Preventive Oncology.

To secure continuous stewardship in the field of cancer prevention requires in part training the next generation of scientists and practitioners effectively. We characterized members and meeting registrants of the American Society for Preventive Oncology and assessed their career needs using an electronic survey. From 380 valid email addresses, 233 respondents (61%) included 143 physicians and 81 respondents with other doctorates. More than one third worked at cancer centers (36%), while others worked at schools of medicine (25%) and public health (17%) and other institutions and businesses (22%). Among all respondents, 52% reported having at least one mentor but time spent advising by mentors was generally low. Many were less than satisfied with the amount of mentoring received (44%) and 52% reported interest in matching with an American Society for Preventive Oncology mentor. All were interested in grantsmanship training but junior and senior respondents differed in their preference for other topics, reflecting needs that change with career advancement. Other analyses focused on aspects of institutional commitment, which did not differ by type of degree, even after age adjustment. However, by gender and degree, men were completely supported by institutional funds more often than women among non-medical doctorates [age-adjusted odds ratio (OR) = 3.3, 95% confidence interval (CI) = 1.1-9.8] but not among physicians (age-adjusted OR = 1.3, 95% CI = 0.5-3.1). Men were also more often in tenure-track positions than women (age-adjusted OR = 1.9, 95% CI = 1.1-3.3). In sum, addressing the career development needs of future leaders in the field by providing career and mentoring sessions at annual meetings may help individuals in the field and enrich the discipline overall.

Adult↗
PubMed2003

Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture.

In the planning of future intervention trials using chemopreventive agents against lung cancer, it is critical to evaluate the effect on biomarkers implicated specifically in lung carcinogenesis. With the use of the H520 and H522 human lung cancer cell lines, the present study showed that treatment with selenium (in the form of methylseleninic acid) inhibited cell growth, arrested cell cycle progression at G(1), and induced apoptosis as a late event. Because H520 cells were more sensitive to selenium than H522 cells (IC(50) of MSA was 2.5 or 10 micro M for H520 or H522 cells, respectively, at 24 h), a panel of nine cell cycle regulatory proteins known to be involved in G(1)-->S transition was assessed by Western analysis using whole cell lysate from H520 cells. These nine proteins (DP1, cdc25A, cyclin A, cyclin B(1), cyclin D(1), cdk1, cdk5, p21(WAF1), and GADD153) have been reported previously by our laboratory to be modulated by MSA in human breast and prostate cancer cells. Our data showed that only four (DP1, cdc25A, p21(WAF1), and GADD153) of nine biomarkers produced the expected changes after treatment of lung cancer cells with MSA. This finding raises the possibility that the molecular targets sensitive to selenium modulation may be tissue specific. Thus, the selection of selenium biomarkers for evaluation in an intervention trial must be based on empirical data derived from the cancer cell type of interest.

Adenocarcinoma↗
PubMed2002

Prostate cancer and selenium.

The important progress achieved in the treatment of prostate cancer comes by exacting significant costs [11, 16-18, 20, 23, 25]. Currently, there is incomplete evidence that the radical interventions at hand significantly reduce the human costs of the disease. Surgery and radiotherapy induce substantial risks of incontinence and impotence. The PSA test has probably decreased the stage at which prostate cancer is diagnosed [15]. Nonetheless, the PSA is a means of earlier detection; it does not elucidate quantitatively distinct modes of treatment. The PSA test is not a means of prostate cancer prevention. The continuing incidence, morbidity, and mortality imposed by this disease strongly indicate that preventive strategies for its control are necessary. Chemoprevention with selenium and other agents offers a promising approach that is undergoing intensive investigation. Randomized trials underway at the authors' center are building on the important clinical trial results reported by Dr. Larry C. Clark. These studies will evaluate the activity of selenium at several points along a continuum ranging from cancerous prostatic tissue in men with diagnosed cancer to premalignant tissue in men with high-grade PIN to healthy tissue in high-risk men with negative biopsy to long-term effects on cancerous tissue in men with frank cancer. These trials will also offer an opportunity for preliminary evaluation of the mechanisms by which selenium treatment could result in the slower development or progression of prostate cancer.

Clinical Trials as Topic↗
PubMedDate not supplied

Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies.

This study investigated the speciation and bioavailability of selenium in yeast-based intervention agents from multiple manufacturers from several time points. Sources of selenized yeast included Nutrition 21 (San Diego, CA), which supplied the Nutritional Prevention of Cancer (NPC) Trial from 1981-1996; Cypress Systems (Fresno, CA; 1997-1999); and Pharma Nord (Vejle, Denmark; 1999-2000), which supplied the Prevention of Cancer by Intervention by Selenium (PRECISE) Trial pilot studies. The low-molecular-selenium species were liberated from the samples by proteolytic hydrolysis followed by separation by ion exchange liquid chromatography and detection by inductively coupled plasma-mass spectrometry. The results for the NPC tablets showed that selenomethionine, together with 3 unidentified selenium compounds, were predominant in the sample hydrolysates. The relative amounts of the 4 selenium species varied (p < 0.05) among several of the 7 tablet batches used during the course of the NPC Trial. In comparison, 5 batches of more recently produced selenized yeasts, which were used as a source of selenium in the PRECISE and other trials, contained less of the unknown compounds and more selenomethionine at 54-60% of the total selenium in the yeasts. One batch of yeast, however (from 1985), which originated from the same producer as the yeast used in the NPC tablets, contained only 27% of selenium in the sample as selenomethionine. Human subjects receiving 200 microg selenium/day in the UK PRECISE Pilot Trial showed a higher concentration (p < 0.01) and higher increase from baseline in plasma selenium than did the same dosage used in the NPC Trial. Differences in intake, speciation, or bioavailability of selenium from the yeast-based supplements in the population groups studied may explain this. Furthermore, the selenium concentration in whole blood from the Danish PRECISE Pilot Trial was higher (p < 0.001) than that obtained with synthetic L-selenomethionine in a comparable group of Danes, both groups having been treated with 300 microg selenium/day.

Anticarcinogenic Agents↗